Affiliation:
1. 1The Institute of Cancer Research, London, United Kingdom.
2. 2Perlmutter Cancer Center, NYU Langone Health, New York, New York.
Abstract
Summary
The prognostic significance of minimal residual disease (MRD) detection in multiple myeloma is well established. Understanding factors that predict for MRD negativity, such as tumor burden, cytogenetic, and immune-related biomarkers, may enable us to improve outcome prediction at diagnosis, and in the future move toward tailored treatment approaches.
See related article by Guerrero et al., p. 2598
Publisher
American Association for Cancer Research (AACR)
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献